Tissue Regenix (GB:TRX) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Tissue Regenix Group PLC, a leader in regenerative medical devices, successfully passed all resolutions at their Annual General Meeting, with overwhelming shareholder support. Their patented decellularisation technology, dCELL®, continues to innovate in the medical field, addressing vital needs in various medical procedures. The company’s acquisition of CellRight Technologies in 2017 has further strengthened its position in the regenerative medicine space.
For further insights into GB:TRX stock, check out TipRanks’ Stock Analysis page.
